PMXSF (Syntara) Tariff Resilience Score: 0/10 (As of Jul. 01, 2026)


PMXSF Syntara Ltd PMXSF
13 GF Score
Price $0.03
! 1 Warning Sign
View Full Analysis

What is Syntara Tariff Resilience Score?

Syntara has the Tariff Resilience Score of 0, which implies that the company might have .

Syntara has

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes Syntara might have .

Syntara  (OTCPK:PMXSF) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

Syntara Tariff Resilience Score Related Terms

PMXSF
13GF Score
Syntara Ltd PMXSF
Tariff Resilience Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Syntara Business Description

Other Exchanges UUDA:GermanySNT:Australia
Address 20 Rodborough Road, Unit 2, Frenchs Forest, Sydney, NSW, AUS, 2086
Syntara Ltd is a clinical-stage drug development company working to bring new and life-changing treatments to patients in need. It is targeting extracellular matrix dysfunction with its expertise in amine oxidase chemistry and other technologies to develop novel medicines for blood cancers and conditions linked to inflammation and fibrosis. The company has various drug candidates in its pipeline such as SNT-5505, SNT-4728, SNT-5382, and SNT-8370 as a potential treatment for cancer, skin scarring and neuroinflammation.
13GF Score

Get the complete analysis for PMXSF

Tariff Resilience Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.03
Price